A phase I first-in-human trial to investigate safety, tolerability and pharmacokinetics of PTI-125 in healthy human volunteers

Trial Profile

A phase I first-in-human trial to investigate safety, tolerability and pharmacokinetics of PTI-125 in healthy human volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs PTI-125 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 24 Oct 2017 According to a Pain Therapeutics media release, this trial was supported with research grant award from the National Institute on Aging, part of the National Institutes of Health.
    • 24 Oct 2017 According to a Pain Therapeutics media release, full results of this study will be presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
    • 24 Oct 2017 Results published in the Pain Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top